Inhibition of endothelial cell migration and angiogenesis by a vascular endothelial growth factor receptor-1 derived peptide

European Journal of Cancer

Volumn 44, Issue 13, 2008, Pages 1914-1921

  Lacal, Pedro M ^a   Morea, Veronica ^b   Ruffini, Federica ^a   Orecchia, Angela ^c   Dorio, Annalisa S ^d   Failla, Cristina M ^a   Soro, Simonetta ^e   Tentori, Lucio ^d   Zambruno, Giovanna ^a   Graziani, Grazia ^d   Tramontano, Anna ^e   D'Atri, Stefania ^a  

^a LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^b CNR   (Italy)

^c INSERM   (France)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Angiogenesis; Endothelial cells; Migration; PlGF; Soluble VEGFR 1; VEGFR 1 activation; VEGFR 1 peptides

Indexed keywords

MEMBRANE BOUND VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; PEPTIDE B3; PEPTIDE DERIVATIVE; PLACENTAL GROWTH FACTOR; SOLUBLE VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 1;

AMINO ACID SEQUENCE; ARTICLE; CELL CULTURE; CELL MIGRATION; CONTROLLED STUDY; CULTURE MEDIUM; DIMERIZATION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; SEQUENCE ANALYSIS; TUMOR VASCULARIZATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; CELL DIFFERENTIATION; CELL MOVEMENT; CELL PROLIFERATION; ENDOTHELIAL CELLS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; PEPTIDE FRAGMENTS; PREGNANCY PROTEINS; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1;

EID: 49549085264     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2008.06.032     Document Type: Article

References (30)

1. Ferrara N., Gerber H., and LeCourter J. The biology of VEGF and its receptors. Nat Med 9 (2003) 669-676
2. Shibuya M., and Claesson-Welsh L. Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. Exp Cell Res 312 (2006) 549-560
3. Kendall R.L., and Thomas K.A. Inhibition of vascular endothelial cell growth factor activity by an endogenously encoded soluble receptor. Proc Natl Acad Sci USA 90 (1993) 10705-10709
4. Kaplan R., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the premestatatic niche. Nature 438 (2005) 820-827
5. Kendall R.L., Wang G., and Thomas K.A. Identification of a natural soluble form of the vascular endothelial growth factor receptor, FLT-1, and its heterodimerization with KDR. Biochem Biophys Res Commun 226 (1996) 324-328
6. Orecchia A., Lacal P.M., Schietroma C., Morea V., Zambruno G., and Failla C.M. Vascular endothelial growth factor receptor-1 is deposited in the extracellular matrix by endothelial cells and is a ligand for the α5β1 integrin. J Cell Sci 116 (2003) 3479-3489
7. Autiero M., Luttun M., Tjwa M., and Carmeliet P. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost 1 (2003) 1356-1370
8. Luttun A., Autiero M., Tjwa M., and Carmeliet P. Genetic dissection of tumor angiogenesis: are PlGF and VEGFR-1 novel anti-cancer targets?. Biochim Biophys Acta 1654 (2004) 79-94
9. Gimbrone M.A. Culture of vascular endothelium. Prog Hemost Thromb 3 (1976) 1-28
10. Tentori L., Vergati M., Muzi A., et al. Generation of an immortalized human endothelial cell line as a model of neovascular proliferating endothelial cells to assess chemosensitivity to anticancer drugs. Int J Oncol 27 (2005) 525-535
11. Berman H.M., Westbrook J., Feng Z., et al. The Protein Data Bank. Nucleic Acids Res 28 (2000) 235-242
12. Dayringer H.E., Tramontano A., Sprang S.R., and Fletterick R.J. Interactive program for visualization and modelling of proteins, nucleic acids and small molecules. J Mol Graph 4 (1986) 82-87
13. Leu S.-J., Lam S.C.-T., and Lau L.F. Pro-angiogenic activities of CYR61 (CCN1) mediated through integrins avb3 and a6b1 in human umbilical vein endothelial cells. J Biol Chem 277 (2002) 46248-46255
14. Del Bufalo D., Trisciuoglio D., Scarsella M., et al. Lonidamine causes inhibition of angiogenesis-related endothelial cell functions. Neoplasia 6 (2004) 513-522
15. Biroccio A., Candiloro A., Mottolese M., et al. Bcl-2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression and in vivo angiogenesis in a breast carcinoma line. FASEB J 14 (2000) 652-660
16. Soro S., Orecchia A., Morbidelli L., et al. A proangiogenic peptide derived from vascular endothelial growth factor receptor-1 acts through α5β1 integrin. Blood 111 (2008) 3479-3488
17. Tan D.C.W., Kini R.M., Jois S.D.S., Lim D.K.F., Xin L., and Ge R. A small peptide derived from Flt-1 (VEGFR-1) functions as an angiogenic inhibitor. FEBS Lett 494 (2001) 150-156
18. Barleon B., Totzke F., Herzog C., et al. Mapping of the sites for ligand binding and receptor dimerization at the extracellular domain of the vascular endothelial growth factor receptor FLT-1. J Biol Chem 272 (1997) 10382-10388
19. Fuh G., Garcia K.C., and de Vos A.M. The interaction of neuropilin-1 with vascular endothelial growth factor and its receptor Flt-1. J Biol Chem 275 (2000) 26690-26695
20. Cai J., Ahmad S., Jiang W.G., et al. Activation of vascular endothelial growth factor receptor-1 sustains angiogenesis and Bcl-2 expression via the phosphatidylinositol 3-kinase pathway in endothelial cells. Diabetes 52 (2003) 2959-2968
21. Autiero M., Waltenberger J., Communi D., et al. Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt-1 and Flk-1. Nat Med 9 (2003) 936-943
22. Zakarija A., and Soff G. Update on angiogenesis inhibitors. Curr Opin Oncol 17 (2005) 578-583
23. Shih T., and Lindley C. Bevacizumab: an angiogenesis inhibitor for the treatment of solid malignancies. Clin Ther 28 (2006) 1779-1802
24. Hochster H.S. Bevacizumab in combination with chemotherapy: first-line treatment of patients with metastatic colorectal cancer. Semin Oncol 33 (2006) S8-S14
25. Roboz G.J., Giles F.J., List A.F., et al. Phase I study of PTK787/ZK222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome. Leukemia 20 (2006) 952-957
26. Cao C., Albert J.M., Geng L., et al. Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer. Cancer Res 66 (2006) 11409-11415
27. Sandberg J.A., Bouhana K.S., Gallegos A.M., et al. Pharmacokinetics of an antiangiogenic ribozyme (ANGIOZYME) in the mouse. Antisense Nucleic Acid Drug Dev 9 (1999) 271-277
28. Luttun A., Tjwa M., Moons L., et al. Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt-1. Nat Med 8 (2002) 831-840
29. An P., Lei H., Zhang J., et al. Suppression of tumor growth and metastasis by a VEGFR-1 antagonizing peptide identified from a phage display library. Int J Cancer 111 (2004) 165-173
30. Bae D.-G., Kim T.-D., Li G., Yoon W.-H., and Chae C.-B. Anti-Flt1 peptide, a vascular endothelial growth factor receptor1-specific hexapeptide, inhibits tumor growth and metastasis. Clin Cancer Res 11 (2005) 2651-2661